Zynerba Pharmaceuticals Shares Spike After Co. Highlights Presentation Of Data From Zygel Study At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
Graybug Vision Shorts Got A Serious Squeeze: What’s Next?
Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn’t stop the stock fr
A Technical Look At Novan’s Stock Amid 80% Spike
Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events.
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crispr Therapeutics AG (NASDAQ:CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and…
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
BeiGene Ltd (NASDAQ:BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (NYSE:JNJ) Imbruvica (ibrutinib)…